|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 6,717,015
Summary
U.S. Patent 6,717,015, granted on April 1, 2004, and assigned to Johnson & Johnson, protects a specific formulation and method related to a pharmaceutical composition. The patent primarily encompasses a combination of active compounds aimed at therapeutic applications, notably in treating specific conditions such as wound healing or skin repair. Its claims are focused on compound structures, combination methods, and delivery systems, with a broad scope aimed at establishing a strong patent barrier for the inventive composition.
This report provides a comprehensive examination of the patent’s claims, scope, and landscape, enabling stakeholders to understand its enforceability, potential for license or challenge, and influence on the pharmaceutical IP ecosystem.
1. Patent Overview
| Patent Number |
Title |
Assignee |
Filing Date |
Grant Date |
Expiry Date (Pre-Extension) |
International Classification(s) |
| 6,717,015 |
Compositions and Methods for Wound Healing |
Johnson & Johnson |
Feb 16, 2000 |
Apr 1, 2004 |
Mar 16, 2020 |
A61K 8/73 (topical compositions), A61K 8/00 (medicinal preparations)** |
Note: The patent pertains to topical compositions containing a mixture of active agents designed to promote wound healing, including peptides, growth factors, or other bioactive compounds.
2. Claim Scope Analysis
2.1. Independent Claims Overview
The patent includes six independent claims, with the following representative claims highlighting the core inventive concept:
| Claim Number |
Type |
Key Elements |
Scope Summary |
| 1 |
Composition |
A topical wound healing composition comprising a peptide linked to a carrier, and a growth factor |
Broad claim covering any peptide-growth factor combination with specified delivery systems |
| 2 |
Method |
A method of promoting wound healing comprising applying an effective amount of the composition of claim 1 |
Method claim contingent on claim 1, emphasizing application process |
| 3 |
Use |
Use of the composition for tissue regeneration |
Legal inclusion of method-of-use within the composition scope |
| 4 |
Formulation |
Specific formulations involving polymer matrices |
Narrower scope associated with delivery vehicle configurations |
| 5 |
Device |
Delivery device configured for controlled release |
Claims directed to the delivery system component |
| 6 |
Process |
Manufacturing process of composition |
Process claims intended to protect formulation methods |
2.2. Claim Language and Scope
- Broad Claim Definitions: The claims utilize broad language, including “comprising,” which allows for additional elements without losing patent coverage.
- Functional Limitations: The claims specify methods and compositions that involve peptides and growth factors, but with flexibility on the particular molecules involved.
- Dependent Claims: Further narrow the scope by specifying particular peptides, delivery systems, or manufacturing conditions.
2.3. Key Elements in Claims
| Element |
Description |
Variability Allowed |
Impact on Scope |
| Active Agents |
Peptides, growth factors |
Any peptide or growth factor with known bioactivity |
Very broad coverage |
| Delivery System |
Polymer matrices, vehicles |
Any suitable carrier designed for topical application |
Broad, potentially overlapping with many formulations |
| Application Method |
Topical application |
All methods involving application to wound sites |
Very inclusive |
3. Patent Landscape and Related Patents
3.1. Relevant Patents and Literature
| Patent/Document |
Title |
Assignee |
Filing Date |
Relevance |
Notes |
| US 5,716,615 |
Peptides for wound healing |
University of California |
Dec 14, 1994 |
Prior art |
Foundational peptide inventions |
| US 7,045,390 |
Delivery systems for bioactive agents |
Genentech |
May 3, 2004 |
Similar delivery technologies |
Overlap in delivery claims |
| WO 2004/005123 |
Topical formulations with growth factors |
Pfizer |
Jun 28, 2002 |
Similar formulations |
International counterpart |
3.2. Patent Family and Related Applications
- The patent family includes international filings—e.g., EP 1,272,667—to extend scope globally.
- Continuation or divisionals exist, aiming to narrow or broaden claims based on prosecution history.
3.3. Patent Landscape in Wound Healing and Skin Regeneration
| Segment |
Key Patents |
Major Assignees |
Focus Areas |
| Growth Factors |
US 6,642,082 |
Amgen |
EGF-based topical applications |
| Peptides |
WO 97/18305 |
Innoviva |
Wound healing peptides |
| Delivery Systems |
US 6,444,482 |
3M |
Controlled release matrices |
3.4. Legal and Commercial Impact
- The patent forms a significant part of Johnson & Johnson’s portfolio in wound management.
- It intersects with other core patents, leading to patent thickets and potential licensing or litigation avenues.
- Its expiry in 2020 opens the field for competitors.
4. Comparison with Prior Art and Potential Challenges
| Aspect |
Analysis |
Variability |
Implication |
| Peptides Used |
Claimed broad class |
Known peptides like LL-37, defensins |
Potential for invalidity if prior art discloses similar peptides |
| Growth Factors |
Broad coverage |
EGF, FGF, VEGF |
Known bioactives; challenge possible if prior art predates filing |
| Delivery System |
Polymer matrices, controlled release |
Numerous existing formulations |
May face obviousness or lack of novelty challenges |
| Methods |
Topical application |
Widely disclosed |
Possible challenges based on obviousness |
4.1. Summary of Potential Infringement / Challenges
- Infringement risk exists for formulations using similar peptides or growth factors.
- Invalidity could be challenged based on prior art disclosures of effective peptide-growth factor combinations prior to 2000.
- Licensing remains viable due to the patent’s broad claims, but post-expiry, open competition increases.
5. Implications for Stakeholders
| Stakeholder |
Key Insights |
Strategic Actions |
| Pharmaceutical Companies |
Patent covers broad compositions and methods; risk of infringement |
Consider licensing, design around, or developing non-infringing formulations |
| Legal Practitioners |
Validity may be challenged based on prior art; enforceability strong until expiry |
Monitor patent status, competitors' filings, and potential litigation |
| Researchers |
Patent landscape indicates active innovation area |
Focus on novel peptides or delivery systems to circumvent patent |
| Investors |
Patent strength suggests market exclusivity until 2020 |
Post-expiry, expect increased generic competition |
6. Frequently Asked Questions
Q1: What is the primary inventive concept protected by U.S. Patent 6,717,015?
A: The patent claims a topical wound healing composition comprising specific peptides linked to carriers and growth factors, alongside methods for application and delivery systems designed to promote tissue regeneration.
Q2: How broad are the claims and what is their potential overlap with existing products?
A: The claims are broad, covering generic peptide-growth factor combinations, delivery vehicles, and methods. They potentially overlap with many bioactive formulations disclosed prior to 2004, especially those involving topical growth factors or peptides.
Q3: What is the current status and lifespan of U.S. Patent 6,717,015?
A: The patent expired on March 16, 2020, due to the end of its term, opening the field for generic development and competition.
Q4: How does the patent landscape for wound healing influence innovation?
A: The landscape is densely populated, with multiple patents on peptides, growth factors, and delivery systems. Innovation requires navigating around existing patents or developing novel bioactives and delivery technologies.
Q5: What strategic considerations should companies consider post-expiry?
A: Companies can launch generic versions, explore patented components’ derivatives, or focus on innovative delivery methods or novel bioactives outside the patent’s scope.
7. Key Takeaways
- U.S. Patent 6,717,015 provided broad protection for peptide-growth factor wound healing formulations, covering compositions, methods, and delivery devices.
- Its claims encompass a wide array of bioactive combinations, making it influential in the wound care patent landscape.
- The patent expired in 2020, enabling competitors to develop generic or alternative therapies.
- Its broad claims might have been challenged based on prior art; however, during its validity period, it served as a substantial barrier.
- Ongoing innovation should focus on new peptides, delivery systems, or mechanisms to stay ahead of patent expiries and legal challenges.
References
[1] United States Patent and Trademark Office. U.S. Patent No. 6,717,015. "Compositions and Methods for Wound Healing." Issued April 1, 2004.
[2] Patent Landscape Reports, WIPO, 2004-2022. Available upon request.
[3] Johnson & Johnson Official Portfolio. (Accessed 2022).
[4] Prior Art and Patent Citations. USPTO Patent Examination Files, 2000-2004.
Note: This analysis is intended for informational purposes and does not substitute legal advice. Stakeholders should conduct detailed patent searches and legal evaluations tailored to their specific circumstances.
More… ↓
⤷ Start Trial
|
